180 related articles for article (PubMed ID: 38212245)
41. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
42. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma.
Greenberg AJ; Rajkumar SV; Larson DR; Dispenzieri A; Therneau TM; Colby CL; Phelps TK; Kumar SK; Katzmann JA; Kyle RA; Slager SL; Vachon CM
Br J Haematol; 2012 May; 157(4):472-5. PubMed ID: 22629552
[TBL] [Abstract][Full Text] [Related]
43. Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.
Steiner N; Göbel G; Michaeler D; Platz AL; Prokop W; Wolf AM; Wolf D; Duftner C; Gunsilius E
Blood Adv; 2021 Mar; 5(6):1746-1754. PubMed ID: 33749761
[TBL] [Abstract][Full Text] [Related]
44. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Richardson PG; Laubach J; Mitsiades CS; Schlossman RL; Ghobrial IM; Munshi NC; Anderson KC
Oncology (Williston Park); 2011 Jun; 25(7):594, 596. PubMed ID: 21888257
[No Abstract] [Full Text] [Related]
45. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
[TBL] [Abstract][Full Text] [Related]
46. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
[TBL] [Abstract][Full Text] [Related]
47. Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
Altrock PM; Ferlic J; Galla T; Tomasson MH; Michor F
JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652561
[TBL] [Abstract][Full Text] [Related]
48. Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance.
Clay-Gilmour AI; Hildebrandt MAT; Brown EE; Hofmann JN; Spinelli JJ; Giles GG; Cozen W; Bhatti P; Wu X; Waller RG; Belachew AA; Robinson DP; Norman AD; Sinnwell JP; Berndt SI; Rajkumar SV; Kumar SK; Chanock SJ; Machiela MJ; Milne RL; Slager SL; Camp NJ; Ziv E; Vachon CM
Blood Adv; 2020 Jun; 4(12):2789-2797. PubMed ID: 32569378
[TBL] [Abstract][Full Text] [Related]
49. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review.
McShane CM; Murray LJ; Landgren O; O'Rorke MA; Korde N; Kunzmann AT; Ismail MR; Anderson LA
Cancer Epidemiol Biomarkers Prev; 2014 Feb; 23(2):332-42. PubMed ID: 24451437
[TBL] [Abstract][Full Text] [Related]
50. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
51. The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions.
Atkin C; Reddy-Kolanu V; Drayson MT; Sapey E; Richter AG
Br J Haematol; 2020 Jun; 189(6):1127-1135. PubMed ID: 31999849
[TBL] [Abstract][Full Text] [Related]
52. Identifying monoclonal gammopathy of undetermined significance from electronic health records.
Tanenbaum HC; Birmann BM; Bertrand KA; Teras LR; Krishnan AY; Pourhassan H; Goldsmith S; Cannavale K; Wang SS; Chao CR
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1755. PubMed ID: 36464325
[TBL] [Abstract][Full Text] [Related]
53. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
Blood Cancer J; 2021 May; 11(5):94. PubMed ID: 34001889
[TBL] [Abstract][Full Text] [Related]
54. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
Alfano G; Fontana F; Colaci E; Messerotti A; Bettelli F; Potenza L; Luppi M; Cappelli G
Transplantation; 2017 Nov; 101(11):e337-e342. PubMed ID: 28731904
[TBL] [Abstract][Full Text] [Related]
56. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
57. Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study.
Rögnvaldsson S; Aspelund T; Thorsteinsdóttir S; Turesson I; Björkholm M; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Jul; 107(1):137-144. PubMed ID: 33840154
[TBL] [Abstract][Full Text] [Related]
58. Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers.
Hofmann JN; Beane Freeman LE; Murata K; Andreotti G; Shearer JJ; Thoren K; Ramanathan L; Parks CG; Koutros S; Lerro CC; Liu D; Rothman N; Lynch CF; Graubard BI; Sandler DP; Alavanja MC; Landgren O
Environ Health Perspect; 2021 Jan; 129(1):17003. PubMed ID: 33404262
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
Caers J; Vekemans MC; Bries G; Beel K; Delrieu V; Deweweire A; Demuynck H; De Prijck B; De Samblanx H; Kentos A; Meuleman N; Mineur P; Offner F; Vande Broek I; Van Droogenbroeck J; Vande Velde A; Wu KL; Delforge M; Schots R; Doyen C;
Ann Med; 2013 Sep; 45(5-6):413-22. PubMed ID: 23767978
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method.
Vachon CM; Murray J; Allmer C; Larson D; Norman AD; Sinnwell JP; Dispenzieri A; Kleinstern G; Visram A; Kyle RA; Rajkumar SV; Slager SL; Kumar SK; Murray DL
Blood Adv; 2022 Jun; 6(12):3746-3750. PubMed ID: 35316833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
